ENB003

DRUG2 trials

Sponsors

ENB Therapeutics, Inc, Canadian Cancer Trials Group

Conditions

CancerMelanomaOvarian CancerOvary CancerPancreatic CancerSolid Tumor

Phase 1

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruitingNCT04205227

ENB Therapeutics, IncCancer, Melanoma, Ovary Cancer +2

Start: 2020-02-18End: 2026-03-31Target: 137Updated: 2024-09-19

Phase 2

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

RecruitingNCT04918186

Canadian Cancer Trials GroupOvarian Cancer

Start: 2022-05-03End: 2026-12-31Target: 60Updated: 2026-07-21

Related Papers

1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study

2023-10-31

CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC).

Journal of Clinical Oncology2023-06-011 citations

Abstract CT267: ENB-003, an ETBR antagonist, in combination with pembrolizumab for advanced solid tumor: The ENBolden trial

Cancer Research2023-04-14

803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors

2020-11-011 citations